HTG Molecular Diagnostics Inc.

4.56+0.0400+0.88%Vol 6.01K1Y Perf -8.51%
Apr 16th, 2021 10:31 DELAYED
BID4.47 ASK4.57
Open4.59 Previous Close4.52
Pre-Market- After-Market-
 - -%  - -
Target Price
14.00 
Analyst Rating
Strong Buy 1.40
Potential %
207.02 
Finscreener Ranking
★★+     48.21
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     43.89
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     36.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap28.34M 
Earnings Rating
Neutral
Price Range Ratio 52W %
7.78 
Earnings Date
12th May 2021

Today's Price Range

4.404.60

52W Range

3.7813.80

5 Year PE Ratio Range

-1.10-1.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.87%
1 Month
-25.41%
3 Months
-29.38%
6 Months
-7.57%
1 Year
-8.51%
3 Years
-90.81%
5 Years
-89.20%
10 Years
-

TickerPriceChg.Chg.%
HTGM4.560.04000.88
AAPL134.13-0.3700-0.28
GOOG2 292.22-4.4400-0.19
MSFT259.48-0.0200-0.01
XOM56.51-0.4700-0.82
WFC43.120.88002.08
JNJ160.730.34000.21
FB306.25-1.5700-0.51
GE13.47-0.0800-0.59
JPM153.601.43000.94
Financial StrengthValueIndustryS&P 500US Markets
4.20
4.50
0.38
0.87
-19.40
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
53.30
-185.40
-168.20
-211.30
-87.04
RevenueValueIndustryS&P 500US Markets
6.32M
1.02
-20.31
26.69
Earnings HistoryEstimateReportedSurprise %
Q03 2020-1.05-1.050.00
Q02 2020-1.20-1.200.00
Q01 2020-1.20-1.200.00
Q04 2019-1.20-0.1587.50
Q03 2019-2.10-2.25-7.14
Q02 2019-0.15-0.17-13.33
Q01 2019-0.17-0.19-11.76
Q04 2018-0.20-0.0765.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.950.00-
6/2021 QR-0.87-2.35Negative
12/2021 FY-3.15-10.53Negative
12/2022 FY-3.89--
Next Report Date12th May 2021
Estimated EPS Next Report-0.95
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume6.01K
Shares Outstanding6.21M
Trades Count62
Dollar Volume870.75K
Avg. Volume159.87K
Avg. Weekly Volume47.73K
Avg. Monthly Volume139.37K
Avg. Quarterly Volume138.54K

HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) stock closed at 4.52 per share at the end of the most recent trading day (a -6.03% change compared to the prior day closing price) with a volume of 65.42K shares and market capitalization of 28.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 108 people. HTG Molecular Diagnostics Inc. CEO is John L. Lubniewski.

The one-year performance of HTG Molecular Diagnostics Inc. stock is -8.51%, while year-to-date (YTD) performance is -5.64%. HTGM stock has a five-year performance of -89.2%. Its 52-week range is between 3.78 and 13.8, which gives HTGM stock a 52-week price range ratio of 7.78%

HTG Molecular Diagnostics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 2.18, a price-to-sale (PS) ratio of 4.85, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.50%, a ROC of -60.18% and a ROE of -102.86%. The company’s profit margin is -87.04%, its EBITDA margin is -168.20%, and its revenue ttm is $6.32 Million , which makes it $1.02 revenue per share.

Of the last four earnings reports from HTG Molecular Diagnostics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.95 for the next earnings report. HTG Molecular Diagnostics Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for HTG Molecular Diagnostics Inc. is Strong Buy (1.4), with a target price of $14, which is +207.02% compared to the current price. The earnings rating for HTG Molecular Diagnostics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

HTG Molecular Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

HTG Molecular Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.14, ATR14 : 0.54, CCI20 : -150.63, Chaikin Money Flow : -0.27, MACD : -0.45, Money Flow Index : 69.05, ROC : -14.56, RSI : 38.47, STOCH (14,3) : 4.15, STOCH RSI : 0.00, UO : 50.48, Williams %R : -95.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of HTG Molecular Diagnostics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
3 (75.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (25.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.50
Strong Buy
1.00

HTG Molecular Diagnostics Inc.

HTG Molecular Diagnostics Inc is a commercial-stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. The company derives revenue from services provided by its VERI/O laboratory and sales of the company's automation systems and integrated next-generation sequencing-based HTG EdgeSeq assays. It operates in one segment and its customers are primarily located in the United States and Europe.

CEO: John L. Lubniewski

Telephone: +1 877 289-2615

Address: 3430 E. Global Loop, Tucson 85706, AZ, US

Number of employees: 108

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

News

Stocktwits